Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

NCT03920618 ↗

Recruiting 150 enrolled Third Affiliated Hospital, Sun Yat-Sen University

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.

Timeline

Start: 2019-02-21
Primary completion: 2024-12-31
Completion: 2024-12-31

Publications

Zhang Y, Xu W, Deng Z, Wang L, Zheng X, Zhu X, Li X, Li J, Shu X, Lai J, Peng L, Xie C. Long-term efficacy and safety of tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir in treating hepatitis B virus-related acute-on-chronic liver failure: A 144-week data analysis. Liver Res. 2024 Oct 24;8(4):295-303. doi: 10.1016/j.livres.2024.10.001. eCollection 2024 Dec.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Entecavir	Small molecule	0.5 mg	Oral
Comparator	Tenofovir disoproxil fumarate	Small molecule	300 mg	Oral
Subject	tenofovir alafenamide	Small molecule	25 mg	Oral

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

Summary

Timeline

Publications

Drugs

Indications